MedTrace Logo

Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease

NCT00708552 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 576

Last updated 2018-07-27

Study results available
· View outcomes & findings →

Summary

The study is designed to investigate the efficacy, safety and tolerability of SB-742457 versus placebo in subjects with mild-to-moderate Alzheimer's disease. SB-742457 is an experimental treatment which increases the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's disease.

Conditions

Interventions

DRUG

SB-742457

investigational drug

DRUG

Donepezil

comparator

DRUG

Placebo

comparator

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-04
Primary Completion
2010-03-01
Completion
2010-03-09

Countries

  • Bulgaria
  • Chile
  • Czechia
  • Estonia
  • Germany
  • Greece
  • Mexico
  • Poland
  • Russia
  • South Africa
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00708552 on ClinicalTrials.gov